CA2090650C - Method of producing tissue factor pathway inhibitor - Google Patents

Method of producing tissue factor pathway inhibitor Download PDF

Info

Publication number
CA2090650C
CA2090650C CA002090650A CA2090650A CA2090650C CA 2090650 C CA2090650 C CA 2090650C CA 002090650 A CA002090650 A CA 002090650A CA 2090650 A CA2090650 A CA 2090650A CA 2090650 C CA2090650 C CA 2090650C
Authority
CA
Canada
Prior art keywords
tfpi
sulfonate
inclusion bodies
exchange chromatography
column
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA002090650A
Other languages
English (en)
French (fr)
Other versions
CA2090650A1 (en
Inventor
Judith A. Diaz-Collier
Mark E. Gustofson
Tze-Chein Wun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Monsanto Co
Original Assignee
Monsanto Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monsanto Co filed Critical Monsanto Co
Publication of CA2090650A1 publication Critical patent/CA2090650A1/en
Application granted granted Critical
Publication of CA2090650C publication Critical patent/CA2090650C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C07K14/8114—Kunitz type inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002090650A 1992-03-02 1993-03-01 Method of producing tissue factor pathway inhibitor Expired - Fee Related CA2090650C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/844,297 US5212091A (en) 1992-03-02 1992-03-02 Method of producing tissue factor pathway inhibitor
US07/844,297 1992-03-02

Publications (2)

Publication Number Publication Date
CA2090650A1 CA2090650A1 (en) 1993-09-03
CA2090650C true CA2090650C (en) 2008-01-29

Family

ID=25292320

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002090650A Expired - Fee Related CA2090650C (en) 1992-03-02 1993-03-01 Method of producing tissue factor pathway inhibitor

Country Status (7)

Country Link
US (1) US5212091A (enExample)
EP (1) EP0559632B1 (enExample)
JP (1) JP3333846B2 (enExample)
AT (1) ATE169957T1 (enExample)
CA (1) CA2090650C (enExample)
DE (1) DE69320389T2 (enExample)
DK (1) DK0559632T3 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378614A (en) * 1989-08-18 1995-01-03 Novo Nordisk A/S Vector and method for making tissue factor pathway inhibitor (TFPI) analogues in yeast
US5849703A (en) * 1990-08-27 1998-12-15 G. D. Searle & Co. Pre-formed anticoagulant heparin/TFPI complexes
US5212091A (en) 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
GB9215541D0 (en) 1992-07-22 1992-09-02 Celltech Ltd Protein expression system
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US5552300A (en) * 1994-01-13 1996-09-03 T Cell Sciences, Inc. T cell antigen receptor V region proteins and methods of preparation thereof
US5824644A (en) * 1994-07-07 1998-10-20 G. D. Searle & Co. Method of attenuating arterial stenosis
US5589359A (en) * 1994-08-05 1996-12-31 Chiron Corporation Chimeric proteins
DE69528591T2 (de) * 1994-08-05 2003-02-20 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Herstellung des inhibitors fuer die komplexbildung des gewebefaktors
US5914316A (en) * 1994-12-16 1999-06-22 Washington University Method of inhibiting intimal hyperplasia
JPH11514334A (ja) * 1995-06-07 1999-12-07 チロン コーポレーション タンパク質の可溶化、精製、および再生の方法
US6242414B1 (en) 1995-06-07 2001-06-05 Chiron Corporation Regulation of cytokine synthesis and release
AU2003200506B2 (en) * 1995-06-07 2007-01-18 G.D. Searle Llc Method of solubilizing, purifying and refolding protein and compositions comprising proteins and solubilizing agents
US5885781A (en) * 1995-06-07 1999-03-23 Chiron Corporation Regulation of cytokine synthesis and release
US20030199450A1 (en) * 2001-04-27 2003-10-23 Chiron Corporation Regulation of cytokine synthesis and release
US5772629A (en) * 1995-10-23 1998-06-30 Localmed, Inc. Localized intravascular delivery of TFPI for inhibition of restenosis in recanalized blood vessels
US5824660A (en) * 1996-06-10 1998-10-20 G. D. Searle & Co. Method of inhibiting glomerulonephritis
US6214333B1 (en) 1997-07-08 2001-04-10 Texas Heart Institute Vasoprotective recombinant adenovirus vector containing a human TFPI gene
AU781717B2 (en) * 1998-04-24 2005-06-09 Csl Behring Gmbh Process for the preparation in pure form of the protease activating blood clotting factor VII, its proenzyme or mixture of both proteins by means of ion-exchange chromatography
US6743600B1 (en) 1999-04-30 2004-06-01 Monsanto Technologies Llc Method of removing N-terminal alanine residues from polypeptides with Aeromonas aminopeptidase
US6794159B1 (en) 1999-04-30 2004-09-21 Pharmacia Corporation Method of removing n-terminal alanine residues from polypeptides with aeromonas aminopeptidase
DE19937218A1 (de) * 1999-08-06 2001-02-08 Aventis Behring Gmbh Verfahren zur Reindarstellung der den Blutgerinnungsfaktor VII aktivierenden Protease, ihres Proenzyms oder eines Gemisches beider Proteine mittels Affinitätschromatographie
EA200400549A1 (ru) * 2001-10-15 2005-02-24 Чирон Корпорейшн Лечение сепсиса введением малых доз ингибитора пути тканевого фактора (tfpi)
ATE528014T1 (de) 2002-06-07 2011-10-15 Dyax Corp Polypeptid mit modifizierten kunitz domains
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
JP4522997B2 (ja) * 2003-08-13 2010-08-11 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｔｆｐｉおよびｔｆｐｉアナログを精製するための改良された方法
EP1729791A2 (en) * 2004-03-17 2006-12-13 Chiron Corporation Treatment of severe community-acquired pneumonia by admistration of tissue factor pathway inhibitor (tfpi)
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
CN101262880A (zh) * 2005-06-24 2008-09-10 德拉格雷丘尔公司 在影响呼吸道的炎症病状中气道施用组织因子途径抑制物
US20080090760A2 (en) * 2005-12-09 2008-04-17 Todd Hembrough Compositions and Methods for Inhibiting Cellular Proliferation
LT1981519T (lt) 2005-12-29 2018-04-25 Dyax Corp. Proteazės slopinimas
WO2009026334A2 (en) * 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
KR101179171B1 (ko) 2008-08-14 2012-09-03 주식회사 운화 산삼 또는 인삼을 포함한 인삼류의 형성층 유래 식물줄기세포주를 유효성분으로 함유하는 간질환의 예방 또는 치료용 조성물
JP2013516389A (ja) * 2009-01-06 2013-05-13 ダイアックス コーポレーション カリクレイン阻害剤による粘膜炎治療
US8088599B2 (en) * 2009-02-06 2012-01-03 Fudan University Nucleic acids encoding genetically modified tissue factor pathway inhibitor (TFPI) and method of making the same
ES2905545T3 (es) 2010-01-06 2022-04-11 Takeda Pharmaceuticals Co Proteínas de unión a calicreína plasmática
IL269565B2 (en) 2011-01-06 2024-06-01 Dyax Corp Plasma kallikrein binding proteins
EP3122782A4 (en) 2014-03-27 2017-09-13 Dyax Corp. Compositions and methods for treatment of diabetic macular edema
CN116077648A (zh) 2015-12-11 2023-05-09 武田药品工业株式会社 血浆激肽释放酶抑制剂及其治疗遗传性血管性水肿发作的用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4421685A (en) * 1980-03-27 1983-12-20 Eli Lilly And Company Process for producing an insulin
US4656249A (en) * 1982-06-10 1987-04-07 Howard Florey Institute Of Experimental Physiology And Medicine Peptides with relaxin activity
US4511502A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4512922A (en) * 1982-12-22 1985-04-23 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
DE3537708A1 (de) * 1985-10-23 1987-04-23 Boehringer Mannheim Gmbh Verfahren zur aktivierung von t-pa nach expression in prokaryonten
US4734362A (en) * 1986-02-03 1988-03-29 Cambridge Bioscience Corporation Process for purifying recombinant proteins, and products thereof
US4966852A (en) * 1987-07-23 1990-10-30 Monsanto Company DNA clone of human tissue factor inhibitor
US4923967A (en) * 1988-09-26 1990-05-08 Eli Lilly And Company Purification and refolding of recombinant proteins
DE3832898A1 (de) * 1988-09-28 1990-04-12 Boehringer Mannheim Gmbh Praeparat von in prokaryonten exprimiertem plasminogenaktivator
US5212091A (en) 1992-03-02 1993-05-18 Monsanto Company Method of producing tissue factor pathway inhibitor
KR950701820A (ko) * 1992-06-11 1995-05-17 로저 에이. 윌리암스 패혈증 및 패혈증-연관 옹고장애의 예방 및 치료(prophylaxs and treatment of sepsis and sepsis-associated coagulation disorders)

Also Published As

Publication number Publication date
DE69320389T2 (de) 1999-03-11
DE69320389D1 (de) 1998-09-24
JP3333846B2 (ja) 2002-10-15
CA2090650A1 (en) 1993-09-03
US5212091A (en) 1993-05-18
DK0559632T3 (da) 1998-10-26
EP0559632A3 (enExample) 1995-03-29
EP0559632A2 (en) 1993-09-08
ATE169957T1 (de) 1998-09-15
JPH07274968A (ja) 1995-10-24
EP0559632B1 (en) 1998-08-19

Similar Documents

Publication Publication Date Title
CA2090650C (en) Method of producing tissue factor pathway inhibitor
AU676145B2 (en) A human kunitz-type protease inhibitor variant
US5312736A (en) Anticoagulant analogues of the tissue factor extrinsic pathway inhibitor (EPI) with reduced affinity for heparin
JP3345420B2 (ja) 新規のヒトクニツ型プロテアーゼインヒビター及びその変異体
AU675926B2 (en) A human kunitz-type protease inhibitor variant
Chand et al. Structure-function analysis of the reactive site in the first Kunitz-type domain of human tissue factor pathway inhibitor-2
Diaz-Collier et al. Refold and characterization of recombinant tissue factor pathway inhibitor expressed in Escherichia coli
EP0621869B1 (en) Human kunitz-type protease inhibitor variants
JPH03255099A (ja) プロテイナーゼ阻害因子、それらの調製方法およびそれらを含有する薬物
Petersen et al. Characterization of human tissue factor pathway inhibitor variants expressed in Saccharomyces cerevisiae
NO177716B (no) Fremgangsmåte for fremstilling av terapeutisk aktive polypeptider, DNA-sekvens, ekspresjonsvektor og antistoff
Bischoff et al. Purification and biochemical characterization of recombinant. alpha. 1-antitrypsin variants expressed in Escherichia coli
US5102995A (en) Dna encoding modified heparin cofactor ii
AU4408493A (en) Prophylaxis and treatment of sepsis and sepsis-associated coagulation disorders
Electricwala et al. Biochemical Characterisation of A Pancreatic Elastase Inhibitor from the Leech Hirudin Aria Manillensis
Gustafson et al. Renaturation and purification of human tissue factor pathway inhibitor expressed in recombinant E. coli
US5028534A (en) DNA clones of human placental plasminogen activator inhibitor
Eaker et al. Des-lysyl Glutamyl and Des-lysyl Pyroglutamyl Ribonucleases. II. Structural Studies
US5118793A (en) Modified heparin cofactor II
Calero et al. Expression of the human complex-forming glycoprotein HC (α1-microglobulin) in Escherichia coli
Frost et al. Purification and partial characterization of an ostrich α1-antichymotrypsin-like serum inhibitor

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed
MKLA Lapsed

Effective date: 20120301